Accelerate Alumni (Cohort 11)
Total funds raised
Cambridge Cancer Genomics developed precision oncology solutions to transform the way cancer patients are treated.
Using simple blood draws, CCG shortened the time required to know whether treatment is working, buying the clinician more time to alter treatment and reduce unnecessary side effects. The technology can detect relapse earlier than standard of care, predict response to therapy, and decrease ineffective treatment regimens. Over time, CCG planned to able to better predict the best therapeutic strategy for cancer patients before they even begin treatment.
In June 2021, Cambridge Cancer Genomics was acquired by Dante Labs.